ESPE Abstracts

Background: Fear of hypoglycemia is a major constraint on achieving a good metabolic control in T1D. Sensor augmented insulin pump therapy with threshold-suspended features (MiniMed 640G-SG) might alleviate burden of hypoglucemia and improve outcomes.Objective and hypotheses: Evaluate the effectiveness of this system to prevent day and night hypoglycemia and its impact on HbA1c in a pediatric population with T1D.Method: Descriptive...

Background: There is limited knowledge in children younger than 6 years of age about the safety and efficacy of CSII treatment during long periods of time.Objective and hypotheses: Evaluate the efficacy and safety of CSII treatment in pre-schoolers with T1D, assess if ISPAD/ADA criteria for good metabolic control are achieved and define general and specific characteristics of the treatment in this range of age.Method: Charts of pat...

Aims: The aims of the study are to evaluate the efficacy and safety of CSII treatment in paediatric patients, to determine if ISPAD criteria for good metabolic control are achieved and to define the general and specific characteristics depending on age and pubertal stage.Methods: Charts of all the patients who started CSII in the last 10 years were reviewed. The cohort consisted of 90 patients (age 10.1±4.4 years, 58% males). Age at start, DM durati...

Background: Anti-islet autoantibodies are predictive and diagnostic markers for type 1 diabetes (T1D). The most frequently determined pancreatic autoantibodies in T1D are anti-glutamic acid decarboxilase (GAD), anti-tyrosine phosphatase (IA-2) and anti-insulin (AAI).Objective and hypotheses: To study whether the pancreatic autoimmunity profile influences the initial presentation of diabetes, its metabolic behaviour and the presence of other autoimmune di...